Cancer treatment trials--past failures, current progress and future prospects

Area of Science:

• Oncology
• Clinical Trials
• Cancer Therapy Evaluation

Background:

• Traditional cancer therapy development relies on tumor response studies, often insufficient for common cancers with small survival impacts.
• Distinguishing effective from ineffective innovations is challenging without large-scale randomized patient comparisons.
• Historical controls and small trials limit definitive evidence for many cancer treatments.

Purpose of the Study:

• To review combined evidence on adjuvant therapy for breast and colorectal cancers.
• To present a meta-analysis of chemotherapy trials in advanced ovarian cancer.
• To emphasize the importance of large randomized trials in cancer treatment evaluation and improvement.

Main Methods:

• Review of combined evidence on adjuvant therapy for breast and colorectal cancer.
• Meta-analysis of published chemotherapy trials in advanced ovarian cancer.
• Discussion of oncologist reluctance towards collaborative clinical research.

Main Results:

• Conclusive evidence that certain adjuvant regimens prolong survival in breast cancer.
• Strong evidence supporting adjuvant therapy for colorectal cancer survival benefits.
• Suggestive evidence for cis-platinum prolonging survival in advanced ovarian cancer.

Conclusions:

• Large randomized trials are essential for evaluating and improving treatments for common cancers.
• Adjuvant therapies show significant survival benefits in breast and colorectal cancers.
• Collaborative clinical research requires addressing oncologists' reluctance to participate.